In Vitro Reconstructed Cornea Testing (RhCE): Principles, Methods, and Applications for Ocular Irrit

In vitro reconstructed cornea testing is a validated, animal-free method for evaluating the eye irritation potential of chemicals, cosmetics, and consumer products using three-dimensional reconstructed human cornea-like epithelium (RhCE) models. Recognized internationally under OECD Test Guideline 492, the method quantifies tissue viability after topical exposure and supports hazard classification under the UN GHS framework as well as safety assessments required by major cosmetic regulations. This article explains the technical principles, applicable sample types, test items, procedural workflow, and typical applications of reconstructed cornea testing.

Technical Overview

In vitro reconstructed cornea testing, also known as RhCE (Reconstructed human Cornea-like Epithelium) testing, is a regulatory-accepted alternative to the traditional rabbit Draize eye irritation test. The test system consists of three-dimensional tissue constructs prepared from human corneal epithelial cells cultured on permeable inserts at an air-liquid interface. Over a cultivation period of approximately two weeks, the cells form a stratified, multi-layered epithelium that closely mimics the barrier properties, morphology, and biochemical behavior of the native human corneal surface.

The core principle of the method is that eye irritation potential correlates with cytotoxicity in the corneal epithelium following short-term topical exposure. After the test substance is applied directly to the tissue surface, cell viability is quantified using the MTT reduction assay. A pronounced loss of viability indicates that the substance would likely damage or irritate the cornea in vivo, while preserved viability supports a conclusion of no eye irritation hazard.

• Test method standardized under OECD Test Guideline 492 (RhCE eye hazard identification), with an updated version OECD TG 492B covering performance standards for liquid and solid chemicals.
• Supports a bottom-up testing strategy to confirm "No Category" substances and a top-down strategy to identify Category 1 (serious eye damage) substances under the UN GHS classification system.
• Fully animal-free methodology aligned with the EU Cosmetics Regulation (EC) No 1223/2009, the 3Rs principle (replacement, reduction, refinement), and modern Integrated Approaches to Testing and Assessment (IATA).
• Applicable to both liquid and solid test substances across cosmetic, chemical, household, and selected medical product contexts.

Testing Samples

Cosmetic Products and Ingredients

Eye-area cosmetics such as mascaras, eyeliners, eye shadows, eye makeup removers, and facial cleansers are among the most frequently tested sample categories. Raw cosmetic ingredients, including surfactants, preservatives, plant extracts, and formulated intermediates, are also routinely evaluated to substantiate eye-area safety claims without animal testing.

Household and Industrial Chemicals

Cleaning agents, laundry detergents, dishwashing liquids, disinfectants, polishes, paints, solvents, and agrochemical formulations can be assessed to determine GHS/CLP eye hazard classification for labeling, safety data sheets, and transport documentation under chemical regulations such as REACH.

Chemical Raw Materials

Pure or technical-grade chemical substances in liquid, viscous, gel, cream, paste, or powder form can be tested directly. Solid substances are typically milled to a fine powder and applied with a sterile aqueous overlay to ensure adequate contact with the tissue surface.

Medical Device and Ophthalmic Product Candidates

Extracts or contact-conditioned media from materials intended for ocular or peri-ocular contact, evaluated as supporting evidence within biocompatibility programs referencing the ISO 10993 series, and early-stage ophthalmic formulations screened for corneal tolerance prior to further development.

Testing Items

• Mean tissue viability after exposure, determined by MTT conversion and expressed as a percentage of the concurrent negative control.
• Eye hazard prediction outcome: "No Category" (no prediction of eye irritation or serious eye damage) versus "Category 1 or Category 2" (classification required, with Cat 1 identification possible directly for certain validated models using method-specific lower viability thresholds).
• Negative and positive control performance, verifying tissue batch sensitivity and assay validity.
• Interference checks for substances that directly reduce MTT or are colored, using freeze-killed tissue controls or colorant controls to correct optical density readings.
• Optional complementary endpoints available on request, including histopathological examination of tissue sections, transepithelial electrical resistance (TEER) for barrier function, and release of inflammatory mediators such as IL-8.

Testing Methods

Test System Preparation

Commercially available validated RhCE models are shipped on nutrient agar and equilibrated in assay medium, typically overnight, before dosing. Each treatment group generally comprises duplicate tissues, and the experiment is performed as two independent runs or with replicate tissues per the applicable performance standards.

Exposure and Post-Treatment Procedure

Liquid test substances are applied at a defined dose volume (commonly 50 to 100 microliters) directly onto the epithelial surface, while solids are applied by mass with a sterile aqueous overlay. Exposure durations range from approximately 10 minutes to several hours depending on the validated protocol and the physical state of the substance. After exposure, tissues are thoroughly rinsed to remove residual material, transferred to fresh medium, and subjected to a post-exposure incubation period, typically up to 18 to 24 hours, to allow recovery and expression of cytotoxic effects.

Cell Viability Measurement

Tissues are transferred to MTT solution, and viable cells reduce the yellow tetrazolium dye to purple formazan crystals. The formazan is extracted with isopropanol, and optical density is measured spectrophotometrically in the 540 to 570 nanometer range. Relative viability is calculated by comparing each treatment group to the mean of the negative control, which is set at 100 percent.

Prediction Model and Classification

Under OECD TG 492, a mean relative viability above 60 percent indicates the substance does not require classification for eye irritation or serious eye damage (No Category). A mean viability of 60 percent or below indicates the substance is predicted to induce eye effects and is classified as Category 1 or Category 2; discrimination between these categories requires confirmatory or follow-up testing, for example with the BCOP method (OECD TG 437) within a defined testing strategy. Substances with extreme pH values of 2.0 or lower or 11.5 or higher are presumptively classified for serious eye damage without testing.

Quality Control and Acceptance Criteria

Standard acceptance criteria include a negative control optical density above the model-specific minimum, positive control viability below the defined threshold (for example, methyl acetate or another suitable reference irritant), and acceptable variability between replicate tissues and runs. Non-specific MTT reduction must remain within specified limits for results to be valid. Studies are conducted by accredited third-party laboratories or in-house facilities operating under GLP where regulatory submission is intended.

Applications

• Cosmetic safety assessment and regulatory dossiers, including eye-area product evaluations and alternative-method evidence for markets prohibiting animal testing such as the European Union.
• GHS/CLP classification and labeling of chemical substances and mixtures for hazard communication, safety data sheets, and dangerous goods transport.
• Formulation screening and optimization during product development, enabling rapid comparison of ingredient alternatives and mitigation of irritation potential before human exposure trials.
• Claim substantiation supporting marketing statements related to eye tolerance and gentleness.
• Supporting biocompatibility evidence for materials and products with intended ocular contact within medical device evaluation frameworks.
• Academic and industrial research into corneal cytotoxicity mechanisms, barrier toxicology, and the development of new alternative test methods.

FAQ

How does reconstructed cornea testing differ from the rabbit Draize eye test?

The Draize test observes clinical signs of eye irritation in live rabbits after instillation of the test substance, whereas RhCE testing measures cell viability in a human-derived corneal tissue model in vitro. The in vitro method eliminates animal use, provides quantitative and highly reproducible results, and avoids species-to-species extrapolation concerns.

Can the test distinguish mild irritants from substances causing serious eye damage?

The base OECD TG 492 method reliably identifies non-irritants (No Category) but does not fully discriminate between UN GHS Category 1 and Category 2 on its own. Updated protocols for certain validated models can identify Category 1 directly, and in all other cases discrimination is achieved through tiered testing with complementary methods such as BCOP (OECD TG 437) or ICE (OECD TG 438) within an integrated testing strategy.

Are there substances that cannot be tested with this method?

Yes. The method is not applicable to gases, aerosols, and highly volatile substances that cannot achieve controlled topical contact. Substances with extreme pH values at or below 2.0 or at or above 11.5 are presumed to cause serious eye damage without testing, and strong oxidizing or reducing substances require specific interference controls.

Is the method accepted by Chinese and international regulators?

The RhCE method is included in the OECD Guidelines for the Testing of Chemicals and is accepted in the European Union, the United States, and other jurisdictions for hazard identification. In China, alternative eye irritation methods are being progressively incorporated into the cosmetics safety assessment framework, and RhCE data are increasingly accepted as supporting evidence in safety dossiers.

How much sample is needed and how long does the test take?

Typical sample requirements are approximately 5 to 20 grams or milliliters depending on the substance type and the number of replicate runs. The standard testing cycle, including equilibration, two independent exposure runs, viability measurement, and reporting, generally requires one to three weeks.